More PRNewswire
View Older Stories View Newer Stories-
UAE TO HOST GAMES OF THE FUTURE 2025
-
Asia Green Fund U.S.-China Green Fund I Partner Conference 2023 is Successfully Held in Beijing
-
Upcoming Acer Swift Series Laptops to Feature Models with New AMD Ryzen AI 300 Series Processors
-
ASHTON-DRAKE RELEASES PREMIUM "RUDOLPH THE RED-NOSED REINDEER®" MASTERPIECE FIGURE COLLECTION
-
HO CHI MINH CITY RIVER FESTIVAL EXPANDS IN SCALE, IGNITING SUMMER TOURISM IN 2024
-
Private equity finds a footing but still searching for momentum as two-year slump bottoms out--Bain & Company's PE Midyear Report
-
Sigma 28-45mm F1.8 Full Frame DG DN Art Lens Announced; YouTube Video First Look, Learn More Info at B&H Photo Video
-
ARUP Files Declaration to Support Lawsuit Challenging the FDA's Rule to Regulate Lab-Developed Tests
-
10 Fitness Guarantees Uninterrupted Gym Access with SARA, Even After Hours
-
MGI Tech's DNBSEQ-E25 and G99 Platforms Set Record for Sequencing Applications on Mount Everest
-
The9 Signed a Definitive Share Purchase Agreement to Invest in AI-Powered Educational Technology Company
-
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Ann
-
NOTICE OF THE TWENTY-FIFTH ANNUAL GENERAL MEETING OF SHAREHOLDERS
-
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
-
Supermicro Liquid-Cooled AI SuperClusters Will Power Large-Scale AI Data Center in Japan
-
LaVie Care Centers Takes Strategic Actions to Position the Company for Long-Term Success Amidst Challenging Skilled Nursing Operating Environment
-
Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatme
-
Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer a
-
China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University
-
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis
-
TECNO exhibits its diverse smartphone and AIoT ecosystem with futuristic AR and AI products at COMPUTEX Taipei 2024, with the concept "Smart of Creation"
-
MSI Unveils New AI and Computing Platforms with 4th Gen AMD EPYC™ Processors at Computex 2024
-
Fast Guard Service Shares Their Experience with Local Business Owner as the Best Security Guard Company in California
-
One in Five European Companies Are Facing Strong Pressure to Transform to Stay Viable
-
FrogData Unveils Major AI Factory Upgrade to Revolutionize Automotive Retail Operations
-
izmostock Unveils Revolutionary Image Solution for Leasing Industry, Driving Unparalleled ROI and User Engagement
-
GIGABYTE Partners with NVIDIA on RTX AI PCs Supporting ACE NIM and Digital Human Technology
-
Miami Beach Inspires this Summer with Film, Fashion and Music Experiences
-
Rokid AR Lite Crowdfunding Surpasses $600,000 with One Day Left for Early Bird Price of $479
-
Discovery of World War II fighter plane sets path for first U.S.-Papua New Guinea Sister City
-
Linker Vision to Accelerate Vision AI Adoption Across Enterprise Applications with Large Vision Models, in Collaboration with NVIDIA
-
ConcertAI to Advance Translational and Clinical Development Solutions in Collaboration with NVIDIA
-
ASRock Rack Launches New Servers Supporting the NVIDIA Blackwell Architecture at COMPUTEX 2024
-
MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer
-
Flamingo Therapeutics Presents Poster at ASCO 2024 on Phase II PEMDA-HN Trial for Head and Neck Squamous Cell Carcinoma (HNSCC)
-
Federal Government Authorizes Institute of Information Management to Certify Data Protection Professionals in Nigeria
-
Tolmar Announces Results From Inaugural Landmark Survey of US Physicians To Assess Current State of Testosterone Replacement Therapy (TRT) and the Impact on Practices and Patient Care
-
Bio-Thera Solutions Presents Clinical Data for BAT8006 (Folate Receptor-alpha-ADC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Trend Micro to Secure AI-Enabled Private Data Centers Worldwide
-
Vention to democratize industrial automation using NVIDIA AI technologies
-
OncoHost Announces New Study on Biomarkers for Renal Cell Carcinoma
-
Fast Guard Service Releases Guide to Choosing the Best Fire Watch Service
-
Sunvozertinib's Global Pivotal WU-KONG1B Study Meets Primary Endpoint in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
-
Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
-
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
-
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
-
CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
-
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
-
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
-
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
